基于非处方药转换制度的医药产品结构调整路径分析——“三医”联动改革政策视角

Analysis on pharmaceutical product structure adjustment path being promoted by OTC switching system based on the three-medical linkage reform policy

目的:探索非处方药(OTC)上市和转换机制,优化“三医”(医疗、医保、医药)联动改革产品结构和推进医药产品结构调整的路径。方法:采用文献回顾与比较分析法,分析OTC转换制度、国外实践经验和“三医”联动改革产品结构调整等。结果:实施OTC转换制度的产品结构调整路径,有助于满足临床价值需求和实现医改政策目标。结论:基于OTC转换制度的医药产品结构调整路径,包括优化“三医”联动改革产品结构、转变需求侧消费行为模式、中药上市转换、拓展药品上市许可持有人(MAH)多元化营销渠道和推进互联网销售新业态等,可满足MAH创新产品生命周期策略的需求,提升药品分类管理效能,实现医药产业高质量发展目标。

Objective:In order to explore the licensing and conversion mechanism of over the counter(OTC),the optimizing pharmaceutical product structure of Three-Medical linkage reform,and the adjusting path of pharmaceutical product structure.Methods:The methods of literature review and comparative analysis were used to analyze the OTC switching system,foreign practical experience,product structure of Three-Medical linkage reform,and so on.Results:It would meet clinical value and achieve medical reform policy goals to carry out product structure adjustment of OTC conversion.Conclusion:Based on OTC switching system the path of pharmaceutical product adjustment were put forward,which include optimizing product structure of the Three-Medical linkage reform,changing drug consumption behavior of demand side,converting the Traditional Chinese Medicine,expanding diversified marketing channel of marketing authorization holder(MAH),and promoting new forms of internet drug sale,it can meet the needs of MAH’s innovative product life cycle strategy,improve the effectiveness of drug bottle management and achieve the high-quality development goals of the pharmaceutical industry.